Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Replacement of extracellular fluid and electrolytes in conditions such as dehydration, hypovolemia, and metabolic acidosis,Maintenance fluid therapy in patients who cannot take oral fluids,Perioperative fluid and electrolyte management
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable as a composite solution; glucose half-life ~1.5-2 h in normal individuals, extended in renal impairment; electrolytes follow body homeostasis.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized via glycolysis and subsequent pathways; electrolytes are excreted or reabsorbed as needed; acetate and gluconate are metabolized to bicarbonate in the liver.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal: ~100% as water, electrolytes, and glucose; no biliary or fecal elimination of active drug components.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
None for water and electrolytes; glucose is not protein bound.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
0.2 L/kg for water; electrolytes distribute according to body compartments (ECF ~0.2 L/kg, ICF ~0.4 L/kg); glucose initial Vd ~0.2 L/kg.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100%.
100% intravenous; not administered by other routes.
No specific dose adjustment for GFR; use with caution in renal impairment due to risk of fluid overload and electrolyte disturbances. Monitor serum potassium, phosphate, and magnesium levels closely. In severe renal impairment (GFR <30 m L/min), consider alternative fluids with lower potassium and phosphate content.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to altered metabolism of dextrose and lactate; monitor glucose and lactate levels. Avoid in patients with lactic acidosis or severe hepatic dysfunction.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion based on body weight: 5-10 m L/kg per dose for maintenance, repeated as needed; typical rate: 100-150 m L/kg/day for fluid maintenance, adjusted for clinical status. Monitor glucose and electrolytes frequently.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to age-related decline in renal function and higher risk of fluid overload. Start at lower infusion rates (100-125 m L/hour) and titrate based on clinical response and monitoring of electrolytes, renal function, and volume status.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Monitor serum electrolytes, fluid balance, and acid-base status closely,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid infusion or large volumes in patients with reduced renal function,Use with caution in patients with diabetes mellitus due to dextrose content
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypernatremia,Hypersensitivity to any component,Severe metabolic alkalosis,Anuria or oliguria (unless due to hypovolemia)
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions with IV administration. However, oral intake should be coordinated with IV therapy to avoid fluid or electrolyte imbalance. In patients with diabetes, adjust oral carbohydrate intake to account for dextrose calories.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemia, particularly in gestational diabetes.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Compatible with breastfeeding. Dextrose and electrolytes are normal milk constituents; no adverse effects expected. M/P ratio not applicable.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No standard dose adjustment required. Increased plasma volume may necessitate higher fluid load; adjust rate based on clinical status, glucose tolerance, and hemodilution.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Isolyte R w/ Dextrose 5% is an isotonic, balanced electrolyte solution with 5% dextrose, providing 170 kcal/L. It is contraindicated in patients with lactate metabolism disorders (e.g., severe hepatic failure) due to lactate content. Monitor serum glucose closely in diabetic patients; dextrose may cause hyperglycemia. Do not administer simultaneously with blood through same IV line due to risk of hemolysis. Check for particulate matter and container leaks before use.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This intravenous solution provides fluids, sugars, and electrolytes to maintain hydration and nutritional balance.,Tell your healthcare provider if you have diabetes, kidney disease, liver disease, or a history of heart failure.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your provider if you feel swelling in your arms or legs, shortness of breath, or rapid weight gain (signs of fluid overload).,Blood sugar and electrolyte levels will be monitored regularly during treatment.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemi. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.